MrMed Logo
Deliver to

Chennai, 600017

Available Brands

Did you find this information helpful?

Author Details
mrmed authentic

Want to know more?
Read Our Editorial Policy

Quick Summary

ENFORTUMAB VEDOTIN

ENFORTUMAB VEDOTIN

Background and Date of approval ENFORTUMAB VEDOTIN

​Enfortumab vedotin-ejfv, marketed as Padcev, is an antibody-drug conjugate (ADC) designed to target Nectin-4, a protein highly expressed in urothelial carcinoma. The U.S. Food and Drug Administration (FDA) granted accelerated approval for this therapy on December 18, 2019, for adult patients with locally advanced or metastatic urothelial cancer who had previously received a PD-1 or PD-L1 inhibitor and platinum-containing chemotherapy. This approval was based on clinical trials demonstrating significant efficacy in this patient population. Subsequent studies, including the EV-301 trial, have provided further evidence supporting its clinical benefit.

Uses of ENFORTUMAB VEDOTIN

  • Treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor and platinum-containing chemotherapy.

How is ENFORTUMAB VEDOTIN administered?

The recommended dosage is 1.25 mg/kg (up to a maximum of 125 mg) administered intravenously over 30 minutes on Days 1, 8, and 15 of a 28-day cycle. Treatment continues until disease progression or unacceptable toxicity occurs.

Side Effects of ENFORTUMAB VEDOTIN

Serious Side Effects:

  • Severe Peripheral Neuropathy: May necessitate dose modification or discontinuation.​
  • Serious Skin Reactions: Including Stevens-Johnson syndrome and toxic epidermal necrolysis; discontinue treatment if these occur.​
  • Hyperglycemia: Can lead to ketoacidosis or hyperosmolar hyperglycemic state; monitor and manage appropriately.​
     

Common Side Effects:

  • Fatigue
  • Nausea
  • Decreased Appetite
  • Diarrhea
  • Rash
  • Alopecia
  • Dysgeusia (altered taste)
  • Dry Eyes

Warnings

  • Peripheral Neuropathy: Monitor patients for symptoms such as numbness or tingling in the hands and feet.​
  • Ocular Disorders: Patients may experience dry eyes or blurred vision; regular ophthalmologic evaluations are recommended.​
  • Hyperglycemia: Monitor blood glucose levels, especially in patients with diabetes or risk factors for hyperglycemia.​
  • Infusion Site Reactions: Observe for redness, swelling, or discomfort at the infusion site during and after administration.​
  • Embryo-Fetal Toxicity: Advise pregnant women of the potential risk to the fetus and recommend effective contraception during treatment.

Precautions

Before initiating therapy, assess patients for pre-existing peripheral neuropathy and monitor for new or worsening symptoms during treatment. Patients with a history of hyperglycemia should have their blood glucose levels closely monitored. Advise patients to use artificial tears or other lubricating ophthalmic treatments to alleviate dry eyes. Women of childbearing potential should use effective contraception during treatment and for at least two months after the final dose.

Word of Advice

Patients should promptly report any new or worsening symptoms, particularly those related to nerve function, skin reactions, or blood sugar levels. Maintaining open communication with healthcare providers ensures timely management of side effects. Adherence to scheduled appointments and monitoring protocols is crucial for safe and effective treatment.

Frequently Asked Questions

Q1.

What is the use of enfortumab vedotin?

Enfortumab vedotin, marketed under the brand name Padcev, is primarily used to treat adults with locally advanced or metastatic urothelial carcinoma, which is the most common type of bladder cancer. It is typically prescribed for patients who have previously received a PD-1 or PD-L1 inhibitor and platinum-containing chemotherapy. Additionally, enfortumab vedotin may be used in combination with pembrolizumab for patients ineligible for cisplatin-containing chemotherapy.

Q2.

Is enfortumab vedotin chemotherapy or immunotherapy?

Enfortumab vedotin is classified as an antibody-drug conjugate (ADC), which is a form of targeted cancer therapy. It combines a monoclonal antibody that specifically targets Nectin-4—a protein highly expressed in urothelial cancer cells—with a cytotoxic agent that disrupts cancer cell division. This mechanism allows it to deliver chemotherapy directly to cancer cells while sparing healthy tissues. Therefore, enfortumab vedotin is distinct from traditional chemotherapy and immunotherapy, representing a hybrid approach that leverages aspects of both treatment modalities.

Q3.

What is the success rate of enfortumab vedotin?

The effectiveness of enfortumab vedotin has been demonstrated in clinical trials. In a pivotal study, enfortumab vedotin achieved an overall response rate (ORR) of 44%, with 12% of patients experiencing a complete response and 32% showing a partial response. The median duration of response was 7.6 months. Furthermore, when combined with pembrolizumab, the ORR increased to approximately 67-68%, with notable improvements in progression-free and overall survival compared to traditional chemotherapy.

Q4.

How much does enfortumab vedotin cost?

The cost of enfortumab vedotin can vary based on dosage, treatment duration, and insurance coverage. In the United States, the price for a 20 mg vial of Padcev is approximately Rs. 1,00,000, with a 30 mg vial costing around Rs. 1,55,000. Given that treatment involves multiple vials per dose, the total expense can be substantial. Patients are encouraged to consult with their healthcare providers and insurance companies to understand their financial responsibilities. Additionally, the manufacturer offers assistance programs to help eligible patients manage treatment costs.

Disclaimer

This content is intended for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

;

Why MrMed?

Directly from

Directly from
Manufacturers

Quick Air

Quick Air
Delivery

Genuine

Genuine
Medicines

Up-to 85%

Up-to 85%
Discount

Why MrMed?

  • Genuine Medicines — Sourced from licensed manufacturers and their authorised distributors, with quality checks at every step.

  • Cold Chain Delivery — Temperature-controlled shipping for medicines that need it, to 4,000+ towns and cities across India.

  • Hard-to-Find Medicines — If a medicine is not available in India, we help you source it and support the documentation and approvals required.

  • Up to 85% Savings — Speciality treatments at a fraction of MRP.

We Create a Way. For You.

Serving customers and shipping medicines only within India.

Living with a serious health condition comes with enough challenges. Finding the right medicine shouldn't be one of them.

MrMed helps patients and caregivers in India buy speciality medicines online for cancer, kidney disease, heart conditions, and other complex long-term illnesses. If a prescribed medicine isn't available in India, we also help source and import it from trusted global suppliers while managing the required documentation and approvals.

From genuine medicine sourcing and cold chain delivery to patient support services, we make it easier to access treatment with confidence. Every step is built around one goal: helping you get the medicines you need, when you need them.

Why Patients Trust MrMed

  • 7,000+ speciality medicines across multiple therapeutic areas like oncology, nephrology, cardiology, and critical care medicines

  • Delivery to 4,000+ towns and cities across India

  • Up to 85% savings on speciality medicines

  • Medicines sourced from licensed manufacturers and authorised suppliers

  • Secure ordering through the MrMed website and app

  • Dedicated support for patients and caregivers

MrMed by the Numbers

The trust placed in MrMed is reflected in the lives we've been able to support.

  • ₹125+ crores saved by our users

  • ₹75 saved every second on cancer medicine, heart conditions, and more

  • Helping patients access treatment across India

Beyond Medicine Delivery

We support patients throughout their treatment journey with services that go beyond medicine delivery.

  • Guidance on Patient Assistance Programs (PAPs)

  • Support for accessing prescribed imported medicines

  • Dedicated customer support before and after your order

  • Assistance in finding difficult-to-access speciality medicines

Recognised for Excellence

MrMed has been recognised by leading industry platforms for our work in improving access to speciality healthcare through trust, innovation, and responsible care.

  • Healthcare Start-up of the Year by the Federation of Indian Chambers of Commerce & Industry (FICCI)

  • ET Pharma Game Changer Award for our contribution to speciality healthcare access

  • Selected for the Google Play Accelerator India 2026 Cohort, joining 20 AI-first startups chosen by Google

  • BW Healthcare 40 Under 40 recognition received by our founders, Dev and Saurab, in different years

  • Recognised among Brands to Watch Out For by Local Samosa

Trusted Healthcare, Verified Standards

MrMed is LegitScript Certified, reflecting our commitment to trusted, transparent, and responsible healthcare services. This certification reinforces our focus on maintaining high standards in online healthcare practices and patient safety.

Start Your Treatment Journey with Confidence

Whether you're ordering a regular prescription or looking for a difficult-to-find speciality medicine, MrMed is here to help.

Explore our catalogue and order medicines online with confidence through the MrMed website or app.

Download the MrMed App For Super-Fast Delivery!

MrMed is India's largest online pharmacy for super speciality medicines, offering an extensive range of drugs that cater to diverse health needs across the country.

MrMed

Genuine medicines delivered all over India

MrMed

Sourced directly from reputable manufacturers

MrMed

Efficient storage for temperature-sensitive medicines

MrMedMrMed

Available on Google Play & App Store